Tag: non cystic fibrosis bronchiectasis market share

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Non-Cystic Fibrosis Bronchiectasis Market Growth From $3.93 Billion In 2026 To $4.91 Billion By 2030 At A CAGR Of 5.7%

The market for non-cystic fibrosis bronchiectasis has demonstrated robust expansion over the past few years. Projections indicate a rise from $3.7 billion in 2025 to $3.93 billion in 2026, reflecting a compounded annual growth rate of 6.4%. Factors contributing to this growth trajectory in the historical period include recurrent respiratory infections, a less pronounced understanding of non-CF bronchiectasis, dependence on conventional diagnostic approaches, insufficient healthcare facility resources, and a slower uptake of sophisticated imaging techniques.

The non-cystic fibrosis bronchiectasis sector is poised for significant expansion over the coming years, projected to reach $4.92 billion by 2030 with a compound annual growth rate of 5.7%. This upward trajectory is fueled by several key factors, including the escalating incidence of chronic respiratory conditions, a greater embrace of artificial intelligence and precision medicine, the burgeoning home healthcare and telemedicine sectors, progress in minimally invasive therapies, and the development of healthcare infrastructure in developing economies. Throughout the forecast period, prominent trends are expected to include a shift towards individualized treatment strategies, increased utilization of remote patient monitoring and telehealth services, a rise in AI-driven diagnostic tools, wider implementation of connected health devices and smart lung monitoring systems, and enhanced integration of data-informed clinical decision support.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

Non-Cystic Fibrosis Bronchiectasis Market Growth Drivers: What Factors Are Accelerating Expansion?

The increasing incidence of respiratory ailments is anticipated to be a key driver for the expansion of the non-cystic fibrosis bronchiectasis market in the future. These respiratory conditions, which can impair breathing and overall lung function, are becoming more common. Factors such as escalating environmental pollution, encompassing both outdoor contaminants and indoor irritants like cigarette smoke, are primarily behind this trend. Furthermore, the growing number of respiratory infections offers avenues for enhancing the comprehension, identification, and treatment of non-cystic fibrosis bronchiectasis through focused strategies and general health initiatives. As an illustration, records from England reveal a substantial surge in scarlet fever notifications during the 2022-2023 season; between weeks 37 and 46, 4,622 reports of Group A Streptococcus infections were logged, with week 46 alone accounting for 851 cases, a notable increase compared to the typical 1,294 notifications observed during the same weeks over the preceding five years, according to the Office for Health Improvement and Disparities in June 2023. Consequently, the escalating rates of respiratory diseases are set to fuel the growth within the non-cystic fibrosis bronchiectasis sector.

Non-Cystic Fibrosis Bronchiectasis Market Segmentation Trends And Revenue Drivers

The non-cystic fibrosis bronchiectasis market covered in this report is segmented –

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types

2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments

3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:

1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT

2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy

3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray

4) By Lung Function: Spirometry, Peak Flow Measurement

5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture

6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels

7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

Non-Cystic Fibrosis Bronchiectasis Market Trends: What Is Shaping Future Industry Growth?

Leading entities within the non-cystic fibrosis bronchiectasis (NCFB) sector are prioritizing the creation of cutting-edge treatments, specifically innovative pharmacological approaches that regulate neutrophil elastase. The objective is to rectify the imbalance between proteases and antiproteases, thereby minimizing chronic tissue deterioration and ensuring enduring management of airway remodeling processes. This novel therapeutic approach targeting neutrophil elastase for chronic airway inflammation represents a sophisticated strategy aimed at controlling the overactivity of neutrophil elastase, a key factor contributing to airway damage and ongoing inflammation in NCFB patients. A prime illustration of this development is the European Commission’s endorsement in November 2025 for Insmed’s brensocatib, marketed as BRINSUPRI. This groundbreaking, once-daily oral medication is the first of its kind to inhibit DPP1. Data from the Phase 3 ASPEN study indicated that the 25 mg dosage led to a 19.4% decrease in annualized exacerbation rates when contrasted with a placebo. Furthermore, it extended the duration until the first exacerbation occurred and resulted in a higher percentage of participants remaining free from exacerbations. Beyond these benefits, the drug significantly slowed the decline in lung function (measured by FEV1) over the 52-week period and presented a favorable safety profile. The most frequently observed side effects encompassed headaches, hyperkeratosis, dermatitis, skin rashes, infections of the upper respiratory tract, and dry skin.

Non-Cystic Fibrosis Bronchiectasis Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Access The Complete Non-Cystic Fibrosis Bronchiectasis Market Report:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

Non-Cystic Fibrosis Bronchiectasis Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Non-Cystic Fibrosis Bronchiectasis Market Through 2030?

The non-cystic fibrosis bronchiectasis market size has experienced strong growth in recent years. It is forecast to increase from $3.7 billion in 2025 to $3.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The historical growth of this market can be attributed to factors such as repeated respiratory infections, limited awareness of non-cf bronchiectasis, a reliance on traditional diagnostic methods, inadequate hospital infrastructure, and the low adoption of advanced imaging technologies.

The non-cystic fibrosis bronchiectasis market is projected to experience robust expansion over the coming years. By 2030, its valuation is anticipated to reach $4.92 billion, expanding at a compound annual growth rate (CAGR) of 5.7%. This anticipated growth during the forecast timeframe stems from several factors, including the increasing occurrence of chronic respiratory illnesses, the greater uptake of AI and precision medicine, the expansion of home healthcare and telemedicine services, innovations in minimally invasive therapies, and the development of healthcare infrastructure in burgeoning economies. Key developments expected within this period encompass a greater embrace of individualized treatment strategies, the wider application of remote patient monitoring and telehealth systems, the increasing utilization of AI-driven diagnostic instruments, the broadening deployment of linked health devices and intelligent lung monitoring systems, and the progressive incorporation of data-informed clinical decision support.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

Which Significant Factors Are Encouraging Growth In The Non-Cystic Fibrosis Bronchiectasis Market?

The increasing occurrence of respiratory illnesses is projected to fuel the expansion of the non-cystic fibrosis bronchiectasis market in the future. Respiratory diseases encompass a variety of conditions that impact the lungs and respiratory system, thereby affecting breathing and overall respiratory function. The growing incidence of respiratory diseases is primarily spurred by escalating environmental pollution, which includes both external contaminants and internal irritants such as tobacco smoke. The widespread presence of respiratory infections offers opportunities to advance the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health endeavors. For instance, in June 2023, according to a report published by the Office for Health Improvement and Disparities, a UK-based governmental body, a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were received from week 37 to week 46 during the 2022-2023 season in England, with 851 notifications received in week 46 alone. This figure is considerably higher compared to an average of 1,294 notifications (ranging from 258 to 2,008) for the same period (weeks 37 to week 46) over the previous five years. Consequently, the rising prevalence of respiratory diseases will drive the growth of the non-cystic fibrosis bronchiectasis market.

Which Segment Divisions Form The Structure Of The Non-Cystic Fibrosis Bronchiectasis Market?

The non-cystic fibrosis bronchiectasis market covered in this report is segmented –

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types

2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments

3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:

1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT

2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy

3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray

4) By Lung Function: Spirometry, Peak Flow Measurement

5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture

6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels

7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

Which Trends Are Shaping The Non-Cystic Fibrosis Bronchiectasis Market Landscape?

Companies active in the non-invasive fat reduction market are prioritizing the creation of advanced technologies, such as muscle-stimulating systems, to improve fat loss and optimize treatment outcomes. Muscle-stimulating technologies denote a fat reduction method utilizing electrical impulses to contract muscles, thereby enhancing fat burning and body toning without surgical intervention. For instance, in April 2024, Cartessa Aesthetics, a US-based provider of innovative aesthetic medical devices, launched PHYSIQ 360, an advanced body contouring technology. PHYSIQ 360 delivers enhanced, customizable fat reduction and muscle-building treatments across diverse skin and body types. It incorporates exclusive sequential thermal and electrical pulse (STEP) technology, combining laser energy (LZR) with proprietary pure beam technology for uniform fat reduction and electrical muscle stimulation (EMS) for effective muscle contractions. The device features up to four independently programmable applicators, allowing for the simultaneous targeting of multiple body areas.

Who Are The Key Market Participants In The Non-Cystic Fibrosis Bronchiectasis Market?

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Access The Complete Non-Cystic Fibrosis Bronchiectasis Market Report:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

Which Region Is The Primary Market For The Non-Cystic Fibrosis Bronchiectasis Market?

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non-Cystic Fibrosis Bronchiectasis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp

Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2026, By The Business Research Company

Body Fat Reduction Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/body-fat-reduction-global-market-report

Fat Replacers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fat-replacers-global-market-report

Lung Cancer Diagnostic And Screening Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Non-Cystic Fibrosis Bronchiectasis Market Progress Between 2026 And 2030?

The non-cystic fibrosis bronchiectasis market size has experienced significant growth in recent years. It is projected to expand from $3.7 billion in 2025 to $3.93 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. The historical market growth can be attributed to factors such as recurring respiratory infections, a lack of awareness regarding non-cf bronchiectasis, a reliance on traditional diagnostic approaches, insufficient hospital infrastructure, and the limited adoption of advanced imaging technologies.

The non-cystic fibrosis bronchiectasis market is projected to experience substantial expansion in the coming years. This market is set to reach $4.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. Several factors will drive this growth during the forecast period, including the increasing occurrence of chronic respiratory conditions, the growing embrace of artificial intelligence and precision medicine, the expansion of home healthcare and telemedicine services, advancements in less invasive treatments, and the development of healthcare infrastructure within emerging economies. Key developments anticipated in the forecast period involve a greater uptake of tailored treatment strategies, increased use of remote patient monitoring and telehealth, the burgeoning application of AI-powered diagnostic tools, broader implementation of connected health devices and smart lung monitoring systems, and the progressing incorporation of data-driven clinical decision support.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

What Leading Drivers Are Supporting The Non-Cystic Fibrosis Bronchiectasis Market Expansion?

The increasing incidence of respiratory illnesses is projected to fuel the expansion of the non-cystic fibrosis bronchiectasis market moving forward. These conditions encompass various disorders impacting the lungs and respiratory system, thereby affecting breathing and overall respiratory function. The surge in respiratory disease prevalence is primarily attributed to heightened environmental pollution, which includes both outdoor contaminants and indoor irritants such as tobacco smoke. The growing occurrence of respiratory infections creates avenues for enhancing the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health endeavors. For example, in June 2023, a report from the Office for Health Improvement and Disparities, a UK-based governmental body, indicated that a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were recorded in England from week 37 to week 46 during the 2022-2023 season, with 851 notifications received in week 46 alone. This figure is considerably higher compared to an average of 1,294 notifications (ranging from 258 to 2,008) for the same period (weeks 37 to 46) over the preceding five years. Thus, the rising prevalence of respiratory diseases will propel the growth of the non-cystic fibrosis bronchiectasis market.

Which Segment Types Are Examined In The Non-Cystic Fibrosis Bronchiectasis Market Segment Study?

The non-cystic fibrosis bronchiectasis market covered in this report is segmented –

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types

2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments

3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:

1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT

2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy

3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray

4) By Lung Function: Spirometry, Peak Flow Measurement

5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture

6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels

7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

What Emerging Trends Are Seen In The Non-Cystic Fibrosis Bronchiectasis Market?

Leading companies operating within the non-cystic fibrosis bronchiectasis (NCFB) market are concentrating on developing advanced solutions, such as innovative neutrophil elastase–modulating pharmacologic interventions, to enhance protease–antiprotease balance, alleviate chronic tissue damage, and support ongoing management of airway remodeling. A novel neutrophil elastase–regulating pharmacologic intervention for chronic airway inflammation signifies a targeted therapeutic strategy designed to adjust excessive neutrophil elastase activity, which is an underlying factor in airway injury and persistent inflammation in NCFB. As an example, in November 2025, Insmed, a US-based biopharmaceutical company, obtained European Commission approval for BRINSUPRI (brensocatib), a first-in-class, once-daily oral DPP1 inhibitor. The 25 mg formulation showcased in the Phase 3 ASPEN trial a 19.4% reduction in the annual exacerbation rate compared to placebo, extended the time to first exacerbation, and resulted in a higher proportion of patients staying exacerbation-free. Moreover, it significantly slowed the decline in lung function (FEV₁) at week 52 and exhibited a favorable safety profile, with frequently noted adverse effects including headache, hyperkeratosis, dermatitis, rash, upper respiratory tract infections, and dry skin.

Which Players Are Part Of The Competitive Landscape Of The Non-Cystic Fibrosis Bronchiectasis Market?

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Get The Full Non-Cystic Fibrosis Bronchiectasis Market Report:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

Which Region Leads The Non-Cystic Fibrosis Bronchiectasis Market In Overall Market Size?

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Non-Cystic Fibrosis Bronchiectasis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2026, By The Business Research Company

Body Fat Reduction Market Report 2026

https://www.thebusinessresearchcompany.com/report/body-fat-reduction-global-market-report

Fat Replacers Market Report

https://www.thebusinessresearchcompany.com/report/fat-replacers-global-market-report

Lung Cancer Diagnostic And Screening Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Non-Cystic Fibrosis Bronchiectasis Market Across 2026–2030?

The non-cystic fibrosis bronchiectasis market size has experienced significant growth in recent years. Its expansion is expected to take it from $3.7 billion in 2025 to $3.93 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.4%. The factors contributing to its historical growth include recurring respiratory infections, limited public understanding of non-CF bronchiectasis, a dependence on traditional diagnostic techniques, insufficient hospital infrastructure, and the slow uptake of advanced imaging technologies.

The market size for non-cystic fibrosis bronchiectasis is anticipated to experience robust expansion over the next few years. It is projected to reach $4.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.7%. The expected growth during this period can be attributed to factors such as the increasing incidence of chronic respiratory conditions, the growing embrace of AI and precision medicine, the expansion of home healthcare and telemedicine, innovations in minimally invasive treatments, and the development of healthcare infrastructure in developing markets. Significant trends for the forecast period include the rising adoption of personalized treatment methods, the increasing implementation of remote patient monitoring and telehealth services, the growing application of AI-powered diagnostic tools, the expanding deployment of connected health devices and smart lungs monitoring, and the progressing integration of data-driven clinical decision support systems.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

What Primary Drivers Are Shaping The Development Of The Non-Cystic Fibrosis Bronchiectasis Market?

The increasing occurrence of respiratory conditions is projected to stimulate expansion in the non-cystic fibrosis bronchiectasis market in the foreseeable future. These ailments involve various disorders impacting the lungs and the entire respiratory system, thereby hindering normal breathing and overall respiratory performance. This upward trend in respiratory disease prevalence largely stems from escalating environmental contamination, encompassing both external pollutants and internal irritants like tobacco smoke. The growing incidence of respiratory infections creates avenues for enhancing the comprehension, detection, and treatment of non-cystic fibrosis bronchiectasis via focused initiatives and public health endeavors. As an illustration, a report released in June 2023 by the Office for Health Improvement and Disparities, a UK-based governmental body, indicated that England recorded 4,622 notifications for scarlet fever Group A Streptococcus bacteria between week 37 and week 46 during the 2022-2023 season, with 851 of these notifications occurring in week 46 alone. This figure significantly surpasses the average of 1,294 notifications (with a range of 258 to 2,008) observed for the identical period (weeks 37 to week 46) throughout the previous five years. Consequently, the increasing occurrence of respiratory illnesses will fuel the expansion of the non-cystic fibrosis bronchiectasis market.

What Segmentation Levels Are Considered In The Non-Cystic Fibrosis Bronchiectasis Market?

The non-cystic fibrosis bronchiectasis market covered in this report is segmented –

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types

2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments

3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:

1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT

2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy

3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray

4) By Lung Function: Spirometry, Peak Flow Measurement

5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture

6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels

7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

What Key Developments And Trends Are Impacting The Non-Cystic Fibrosis Bronchiectasis Market?

Leading companies in the non-cystic fibrosis bronchiectasis (NCFB) market are concentrating on developing advanced solutions, such as novel neutrophil elastase–regulating pharmacologic interventions, to enhance the protease–antiprotease balance, lessen chronic tissue damage, and support ongoing management of airway remodeling. A novel neutrophil elastase–regulating pharmacologic intervention for chronic airway inflammation describes a targeted therapeutic approach designed to moderate excessive neutrophil elastase activity, which is a fundamental driver of airway injury and persistent inflammation in NCFB. For example, in November 2025, Insmed, a US-based biopharmaceutical company, obtained European Commission approval for BRINSUPRI (brensocatib), a first-in-class, once-daily oral DPP1 inhibitor. The 25 mg formulation demonstrated a 19.4% reduction in annual exacerbation rate compared to placebo in the Phase 3 ASPEN trial, extended the time to the first exacerbation, and resulted in a higher proportion of patients remaining exacerbation-free. Moreover, it significantly mitigated the decline in lung function (FEV₁) at week 52 and displayed a favorable safety profile, with commonly reported adverse effects including headache, hyperkeratosis, dermatitis, rash, upper respiratory tract infections, and dry skin.

Which Leading Firms Are Contributing To The Growth Of The Non-Cystic Fibrosis Bronchiectasis Market?

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Read the full non-cystic fibrosis bronchiectasis market report here:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

How Does The Non-Cystic Fibrosis Bronchiectasis Market Perform Across Major Global Regions?

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Non-Cystic Fibrosis Bronchiectasis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp

Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2026, By The Business Research Company

Body Fat Reduction Global Market Report

https://www.thebusinessresearchcompany.com/report/body-fat-reduction-global-market-report

Fat Replacers Global Market Report

https://www.thebusinessresearchcompany.com/report/fat-replacers-global-market-report

Lung Cancer Diagnostic And Screening Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the non-cystic fibrosis bronchiectasis market from 2026–2035 with trusted insights from The Business Research Company

How much is the Non-Cystic Fibrosis Bronchiectasis Market valued at in 2026, and what valuation is forecast for 2030?

The non-cystic fibrosis bronchiectasis market has experienced substantial expansion in recent years. Its valuation is anticipated to rise from $3.7 billion in 2025 to $3.93 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.4%. This historic growth is largely due to factors including recurrent respiratory infections, restricted understanding of non-CF bronchiectasis, a dependence on established diagnostic techniques, insufficient hospital infrastructure, and the limited embrace of advanced imaging technologies.

The non-cystic fibrosis bronchiectasis market is projected to experience substantial expansion in the coming years. By 2030, its value is forecast to reach $4.92 billion, growing at a compound annual growth rate (CAGR) of 5.7%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing incidence of chronic respiratory conditions, the wider adoption of AI and precision medicine, the expansion of home healthcare and telemedicine services, progress in minimally invasive treatment options, and the enhancement of healthcare infrastructure within developing economies. Key trends anticipated during this period involve the increasing embrace of personalized treatment strategies, greater integration of remote patient monitoring and telehealth solutions, a rise in the application of AI-powered diagnostic instruments, broader deployment of connected health devices and smart lung monitoring systems, and the progressive integration of data-driven tools for clinical decision support.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

What Drivers Are Influencing The Growth Of The Non-Cystic Fibrosis Bronchiectasis Market?

An increasing incidence of respiratory illnesses is projected to fuel expansion in the non-cystic fibrosis bronchiectasis market moving ahead. These diseases encompass various ailments that target the lungs and respiratory tract, thereby impairing respiration and general respiratory performance. The growing occurrence of respiratory conditions is chiefly propelled by escalating environmental contamination, involving both external pollutants and internal irritants like tobacco smoke. This surge in respiratory infections offers prospects for enhancing the comprehension, identification, and treatment of non-cystic fibrosis bronchiectasis via focused initiatives and public health campaigns. As an illustration, in June 2023, data from a report by the Office for Health Improvement and Disparities, a UK government agency, indicated that a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were recorded from week 37 to week 46 in the 2022-2023 season in England, with 851 notifications specifically in week 46 alone. This figure represents a considerable increase when contrasted with an average of 1,294 notifications (ranging from 258 to 2,008) for the identical period (weeks 37 to week 46) over the preceding five years. Consequently, the increasing occurrence of respiratory ailments is set to boost the expansion of the non-cystic fibrosis bronchiectasis market.

What Segments Are Included Within The Non-Cystic Fibrosis Bronchiectasis Market?

The non-cystic fibrosis bronchiectasis market covered in this report is segmented –

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types

2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments

3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:

1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT

2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy

3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray

4) By Lung Function: Spirometry, Peak Flow Measurement

5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture

6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels

7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

Which Innovation Trends Are Advancing Developments Within The Non-Cystic Fibrosis Bronchiectasis Market?

Key companies operating in the non-cystic fibrosis bronchiectasis (NCFB) market are concentrating on developing advanced solutions, such as novel pharmacologic interventions that regulate neutrophil elastase, to enhance protease–antiprotease balance, alleviate chronic tissue damage, and support ongoing control of airway remodeling. This type of novel neutrophil elastase–regulating pharmacologic intervention for chronic airway inflammation represents a targeted therapeutic approach designed to modify excessive neutrophil elastase activity, which is a fundamental contributor to airway injury and persistent inflammation in NCFB. As an illustration, in November 2025, Insmed, a US-based biopharmaceutical company, secured European Commission approval for BRINSUPRI (brensocatib), a groundbreaking, once-daily oral DPP1 inhibitor. The 25 mg formulation, demonstrated in the Phase 3 ASPEN trial, led to a 19.4% reduction in annual exacerbation rate compared to placebo, extended the duration to the first exacerbation, and showed a greater proportion of patients staying exacerbation-free. Moreover, it significantly mitigated the decline in lung function (FEV1) at week 52 and presented a favorable safety profile, with common adverse effects reported including headache, hyperkeratosis, dermatitis, rash, upper respiratory tract infections, and dry skin.

Who Are The Top-Performing Companies In The Non-Cystic Fibrosis Bronchiectasis Market In Recent Years?

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

How Does The Non-Cystic Fibrosis Bronchiectasis Market Perform Across Major Global Regions?

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-Cystic Fibrosis Bronchiectasis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp

Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2026, By The Business Research Company

Bronchoscope Market Report 2026

https://www.thebusinessresearchcompany.com/report/bronchoscope-global-market-report

Idiopathic Pulmonary Fibrosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Cystic Fibrosis Cf Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model